Exagen Revenue Rises 7% to $18.4 Million in Third Quarter 2026
Exagen reported Q3 2026 revenue of $18.4M, up 7% YoY, with a net loss of $6.3M. Gross margin was 58.8%, and adjusted EBITDA loss was $1.9M. The company maintained its 2026 revenue guidance of $72M to $75M. AVISE CTD's average selling price rose to $451 per test, marking 14 consecutive quarters of growth.
How this was made
The 30-second read
Why it matters
The earnings release shows modest top‑line growth but widening losses, keeping the stock under pressure.
Market read
First‑time earnings disclosure for a micro‑cap; relevant for niche biotech traders.
What to watch
Potential upside from upcoming myositis launch in early 2027 and AI platform integration.
Background
Exagen Inc. (XGN) is a small‑cap diagnostics company focused on rheumatology testing.
Ticker impact
Exagen reported Q3 2026 revenue of $18.4 million, up 7% YoY, and reiterated full‑year guidance of $72‑$75 million.
likely modest downside as market prices in the unchanged guidance and ongoing losses
Revenue growth is modest for a micro‑cap; loss widening may pressure the stock despite guidance consistency.
Market effects
Provides a data point on the niche rheumatology diagnostics market, but limited impact on broader biotech sector.
Primarily U.S. micro‑cap investors; no broader regional effect.
Minimal global relevance beyond niche diagnostic space.
Counterpoint
If the AI‑enabled workflow platform drives cost efficiencies, the company could exceed guidance and rally.
Key entities
- companyExagen Inc.
Rheumatology diagnostics firm reporting Q3 2026 results.
